GlassScriptPhysician profile
Kumar Kalapatapu
NPI 1154324127
$18,788.27
in general payments reported to CMS, 2019-2025
42 companies · $2,358 in 2025
The $2,358 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,257 · 2020: $1,672 · 2021: $3,221 · 2022: $2,571 · 2023: $3,590 · 2024: $2,119 · 2025: $2,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,066.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,212.49 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,961.21 | 2019-2025 | Jardiance |
| Medtronic, INC. | $1,949.42 | 2021-2025 | Micra, Onyx Frontier, Reveal Linq |
| Abbott Laboratories | $1,510.53 | 2019-2025 | Jot Dx, Aveir |
| Amgen INC. | $1,326.22 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $840.67 | 2019-2025 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $813.91 | 2019-2023 | Xarelto |
| Medtronic Vascular, INC. | $607.96 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $508.90 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $474.60 | 2019-2025 | |
| Biotronik INC. | $432.87 | 2019-2022 | |
| Abiomed | $269.41 | 2023-2024 | Impella |
| Novo Nordisk INC | $250.00 | 2021-2022 | |
| Shockwave Medical, INC | $244.31 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Scientific Affairs, LLC | $237.40 | 2023 | Xarelto |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Kalapatapu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.